| Symbol | BCDA |
|---|---|
| Name | BIOCARDIA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 320 SOQUEL WAY, SUNNYVALE, California, 94085, United States |
| Telephone | +1 650 226-0120 |
| Fax | — |
| — | |
| Website | https://www.biocardia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000925741 |
| Description | BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack. Additional info from NASDAQ: |
(80% Positive) BIOCARDIA, INC. (BCDA) Provides Update on Hotel for ischemic heart failure
Read moreBioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
Read moreDirector Altman Peter 🟢 acquired 800 shares of BioCardia, Inc. (BCDA) at $1.09 Transaction Date: Sep 03, 2026 | Filing ID: 029732
Read moreBioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
Read moreDirector Altman Peter 🟢 acquired 5.4K shares of BioCardia, Inc. (BCDA) at $0.93 Transaction Date: Aug 17, 2026 | Filing ID: 028307
Read moreDirector Altman Peter 🟢 acquired 1.9K shares of BioCardia, Inc. (BCDA) at $0.92 Transaction Date: Aug 13, 2026 | Filing ID: 027743
Read moreBioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
Read moreDirector Altman Peter 🟢 acquired 5.0K shares of BioCardia, Inc. (BCDA) at $0.78 Transaction Date: Jul 29, 2026 | Filing ID: 024925
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05491681 | AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acut… | Phase1 | ARDS, Human | Withdrawn | 2026-01-04 | 2026-01-04 | ClinicalTrials.gov |
| NCT06258447 | CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With R… | Na | Ischemic Heart Failure | Recruiting | 2024-08-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT05925608 | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchy… | Phase1 | Heart Failure, Systolic | Active_Not_Recruiting | 2023-08-23 | 2027-12-01 | ClinicalTrials.gov |
| NCT03455725 | CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial | Na | Refractory Angina | Active_Not_Recruiting | 2021-06-30 | 2027-12-01 | ClinicalTrials.gov |
| NCT02438306 | CardiAMP™ Cell Therapy for Heart Failure Trial | Phase3 | Heart Failure, Systolic | Completed | 2016-12-01 | 2025-06-01 | ClinicalTrials.gov |
| NCT00507468 | Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic My… | Phase1 | Ventricular Dysfunction | Completed | 2005-12-01 | 2009-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham | Other | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Autologous cell therapy | Drug | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Diagnostic Catheterization | Other | Phase PHASE1 | Heart Failure, Systolic | ACTIVE_NOT_RECRUITING | NCT05925608 |
| CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) | Other | Phase PHASE1 | Heart Failure, Systolic | ACTIVE_NOT_RECRUITING | NCT05925608 |
| Sham Treatment | Drug | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| CardiAMP Cell Therapy System | Drug | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| intravenous delivery of allogeneic bone marrow-derived MSCs | Other | Phase PHASE1 | ARDS, Human | WITHDRAWN | NCT05491681 |
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | Drug | Approved | Ischemic Heart Failure | RECRUITING | NCT06258447 |
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | DEVICE | Approved | Ischemic Heart Failure | RECRUITING | NCT06258447 |
| intravenous delivery of allogeneic bone marrow-derived MSCs | BIOLOGICAL | Phase PHASE1 | ARDS, Human | WITHDRAWN | NCT05491681 |
| Sham Treatment | OTHER | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| CardiAMP Cell Therapy System | DEVICE | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| Sham | OTHER | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Autologous cell therapy | BIOLOGICAL | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Transendocaridal Transplantation of Autologous Bone Marrow | PROCEDURE | Phase PHASE1 | Ventricular Dysfunction | COMPLETED | NCT00507468 |